DE3200273C2 - L-Phenylalanyl-L-alanyl-L-leucin und dieses Tripeptid enthaltende pharmazeutische Mittel zur Erhöhung der Virusimmunität und der Tumorabwehrkraft - Google Patents
L-Phenylalanyl-L-alanyl-L-leucin und dieses Tripeptid enthaltende pharmazeutische Mittel zur Erhöhung der Virusimmunität und der TumorabwehrkraftInfo
- Publication number
- DE3200273C2 DE3200273C2 DE3200273A DE3200273A DE3200273C2 DE 3200273 C2 DE3200273 C2 DE 3200273C2 DE 3200273 A DE3200273 A DE 3200273A DE 3200273 A DE3200273 A DE 3200273A DE 3200273 C2 DE3200273 C2 DE 3200273C2
- Authority
- DE
- Germany
- Prior art keywords
- tripeptide
- phenylalanyl
- alanyl
- leucine
- pharmaceutical agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008177 pharmaceutical agent Substances 0.000 title claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 title description 6
- 230000036039 immunity Effects 0.000 title description 5
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 title description 4
- 241000700605 Viruses Species 0.000 title description 4
- 239000000654 additive Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WJRLIVKLXYDXHQ-UHFFFAOYSA-N acetic acid;butan-1-ol;ethyl acetate;hydrate Chemical compound O.CC(O)=O.CCCCO.CCOC(C)=O WJRLIVKLXYDXHQ-UHFFFAOYSA-N 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 241001233037 catfish Species 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT48241/81A IT1148005B (it) | 1981-04-09 | 1981-04-09 | Tripeptide nelle sue sei combinazioni amminoacide alania fenilalanina e leucina in particolare fenil-alanina-alanina-leucina (p-a-l) aventela proprieta' di esaltare l'immunita' antivirale ed antitumorale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3200273A1 DE3200273A1 (de) | 1982-10-21 |
| DE3200273C2 true DE3200273C2 (de) | 1984-01-19 |
Family
ID=11265432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3200273A Expired DE3200273C2 (de) | 1981-04-09 | 1982-01-07 | L-Phenylalanyl-L-alanyl-L-leucin und dieses Tripeptid enthaltende pharmazeutische Mittel zur Erhöhung der Virusimmunität und der Tumorabwehrkraft |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS57192349A (enExample) |
| DE (1) | DE3200273C2 (enExample) |
| IT (1) | IT1148005B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4621135A (en) * | 1983-12-08 | 1986-11-04 | Yeda Research & Development Company, Ltd. | Novel THF compositions |
| DK53291D0 (da) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
| ES2119987T3 (es) * | 1993-03-22 | 1998-10-16 | Leonida Grippa | Derivados monoaceticos de los peptidos leu-phe-ala y ala-leu-phe y su uso en la identificacion y la destruccion de celulas tumorales y celulas infectadas por virus. |
| US6602856B1 (en) * | 1995-01-17 | 2003-08-05 | J. Mark Quillan | Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6808552A (enExample) * | 1967-06-30 | 1968-12-31 |
-
1981
- 1981-04-09 IT IT48241/81A patent/IT1148005B/it active
-
1982
- 1982-01-07 DE DE3200273A patent/DE3200273C2/de not_active Expired
- 1982-04-08 JP JP57058949A patent/JPS57192349A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0364512B2 (enExample) | 1991-10-07 |
| IT8148241A0 (it) | 1981-04-09 |
| DE3200273A1 (de) | 1982-10-21 |
| JPS57192349A (en) | 1982-11-26 |
| IT1148005B (it) | 1986-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69832158T2 (de) | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 | |
| DE69024965T2 (de) | Dehydrodidemnin b | |
| DE69022953T2 (de) | Zusammensetzungen zur Behandlung von Fettablagerungen. | |
| DE69418181T2 (de) | Cytokine dämpfende substanzen | |
| DE69003168T2 (de) | Isolierung und Strukturbestimmung des zytostatischen linearen depsipeptiden Dolastatin 13 und Dehydrodolastatin 13. | |
| DE3851203T2 (de) | Gebrauch von GHL-Cu Derivaten für die Herstellung eines Medikaments zur Stimulierung des Haarwachstums. | |
| DE3750432T2 (de) | IL-1 alpha Derivate und Medikamente. | |
| DE3328262A1 (de) | Arzneimittelzubereitung zur besserung von krebssymptomen | |
| EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
| DE69116321T2 (de) | Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält | |
| DE2954675C2 (de) | Verwendung von Polypeptiden zur Bekämpfung von Krebs | |
| DE3881467T2 (de) | Vasokonstriktor-Peptid. | |
| DE69402576T2 (de) | Cytotoxische und antivirale Verbindung | |
| DE69330268T2 (de) | Hämoregulierende peptide | |
| DE3538619C2 (de) | Pharmazeutische Verwendung eines Isomeren des 4-Hydroxyprolin | |
| DE69023559T2 (de) | Derivate von Muramyldipeptid. | |
| DE804227T1 (de) | Neue anwendungen von lysozym-dimer | |
| DE3200273A1 (de) | Tripeptide, aufgebaut aus den drei aminosaeuren alanin, phenylanin und leucin, und pharmazeutische mittel, die diese tripeptide enthalten. | |
| DE3881198T2 (de) | Antiviraler wirkstoff. | |
| DE3684868D1 (de) | Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung. | |
| DE69120396T2 (de) | Neue verwendung von linomide (r) | |
| DE2633976A1 (de) | Tripeptidderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
| CH680070A5 (enExample) | ||
| DE3239710C2 (de) | Peptid mit Nerven-regenerierenden Eigenschaften | |
| DE2710455C2 (de) | N-Acetylmuramyl-L-alanyl-D-glutaminsäure-alpha-methylamid, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| OR8 | Request for search as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8180 | Miscellaneous part 1 |
Free format text: DIE BEZEICHNUNG LAUTET RICHTIG: TRIPEPTIDE, AUFGEBAUT AUS DEN DREI AMINOSAEUREN ALANIN, PHENYLALANIN UND LEUCIN, UND PHARMAZEUTISCHE MITTEL, DIE DIESE TRIPEPTIDE ENTHALTEN. |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |